Background: Mutations in parasite enzymes and sub-optimal dosing associated with poor quality drug administration are considered major causes of parasitological resistance to sulfadoxine-pyrimethamine in the treatment of malaria.
INTRODUCTION
Parasitological resistance to sulfadoxine-pyrimethamine is associated with mutations in parasite dihydrofolate reductase conferring resistance to pyrimethamine and dihydrofolate synthase for sulfadoxine resistance respectively (1, 2) . The prolonged half-life of sulfadoxine-pyrimethamine may exert undue pressure for a considerable time following fall of blood concentration below a critical threshold. Poor quality drug administration associated with suboptimal dosing is a major cause of resistance in disease endemic regions such as Sub-Sahara Africa (3) . The use of sulphur-based antibiotics such as sulphonamides in the management of bacterial infections may complicate management leading to high rate of parasitological failure. Statin treatment causes the exclusion of lipid rafts which are cholesterol and sphingolipid enriched membrane domains that play a role in endovacuolation and macromolecular transport during malaria infection (4) . Simvastatin is known to suppress proliferation of natural killer cell activity in vitro (5) (6) (7) and function as T-cell co-stimulator by binding to leukocyte function antigen 1 (LFA-1) which is thought to have a role in immunity to blood stages of malaria (8, 9) . In view of the foregoing, it was hypothesized that no mean difference in parasitological response exists between malaria patients treated with sulfadoxine-pyrimethamine plus simvastatin and those treated with sulfadoxinepyrimethamine alone. Hence, the present study evaluated the effects of simvastatin in modulating parasitological response to sulfadoxine-pyrimethamine in the treatment of malaria.
METHODS

Subjects:
The subjects selected for this study were patients in attendance at primary health facilities (n = 60) suffering from malaria infection, confirmed using thick blood films and immunological test (Paracheck PI ® ). A rapid qualitative two site sandwich immunochromatographic dipstick assay, (Paracheck PI ® ),was employed for the determination of Plasmodium falciparum specific histidine rich protein-2 (PfHRP-2) in whole blood samples. This was in view of the fact that classical method of diagnosis by microscopy involving examination of thin and thick blood smears was time consuming and prone to false negative readings. 
Results
The baseline characteristics of subjects in the test and control groups at presentation are as shown in Table 1 . Table 2 and Figure 1 revealed statistically significant difference (p<0.05) in the low, mid and high level parasitological resistance (RI, RII, RIII) between the test and control groups.There was a statistically significant difference (p<0.05) between test and control groups in late parasitological failure (LPF).
DISCUSSION
The incidence of low to high level parasitological resistance (RI + RII + RIII) and late parasitological failure varies from 21.4% and 4.4% in the test subjects to 54.9% and 11.4% in the control treated with sulfadoxine-pyrimethamine. A Malawian study reported parasitological resistance rates (RII and RIII) which range from 7% to 19%, though 80% of parasitological response is at the RII level (10) . The said study revealed that overall resistance (RII + RIII) rates are slightly higher in the north than in the central and southern regions of Malawi. Higher resistance rates are observed during the rainy than dry season. However, the above differences are not statistically significant. Another study evaluated in vivo Plasmodium falciparum response to sulfadoxine-pyrimethamine and reveals that 6% exhibited RII parasitological resistance and 3% late parasitological failure.
A previous study in South-West Nigeria reported low to high level parasitological resistance (RI + RII + RIII) in subjects treated with sulfadoxine-pyrimethamine alone, which is readily detectable by the functional viability estimate ex vivo (11) . The functional viability in isolates sensitive to sulfadoxine-pyrimethamine becomes significant by 16-20 hours after drug administration and viable parasites are still evident after 36 hours in some isolates.
Interestingly, the results of conventional methods employed in the present study correlate with above functional viability estimates ex vivo. The finding of viable circulating parasites at 30 to 36 hours after sulfadoxine-pyrimethamine administration is not surprising. This is because the anti-malarial activity of this drug combination and other anti-malarial anti-folates appears to be stage specific and continues to the late stages of the asexual cycle (12) . The implication is that during the critical early phase of drug administration, and also during early infection, sulfadoxine-pyrimethamine may not readily arrest the development of young ring forms to the potentially damaging mature or late stages which sequester in internal organs and are partly responsible for the adverse consequences of falciparum infection (13) . (14) . Spontaneous mutations which confer a marked reduction in pyrimethamine susceptibility occur at relatively high frequency in natural populations.
Anti-malarial drug resistance to sulfadoxine-pyrimethamine involves a right shift in
Thus, the therapeutic use of sulfadoxine-pyrimethamine provides a strong selective pressure to the emergence of resistance. The recrudescent isolates show a marked reduction in susceptibility when tested in vitro because the minimal parasiticidal concentration of these compounds for the sensitive parasites cannot inhibit development of the resistant mutants.
Again, there would be no therapeutic effect, if patients with such isolates are re-treated with the drug to which the malaria parasites have developed resistance. The emergence of sulfadoxine-pyrimethamine resistant falciparum malaria as confirmed in previous studies is seen in control subjects treated with sulfadoxine-pyrimethamine who present in this study (15) .
A receptor identified as scavenger receptor, class B, type I (SR-BI) known to help the malaria parasite sneak inside to fully develop; has been shown to play a critical role in Plasmodium hepatocyte infection (16, 17) . However, it is further postulated that SR-BI may have been selected for evolutionary reason, considering the direct or indirect role it plays in providing cholesterol needed by the malaria parasites for biogenesis of their cell membranes.
Intriguingly, sporozoites enter the liver through a resident macrophage, bypassing the liver's primary defense mechanism, due to the role of circumsporozoite protein (CSP) in preventing respiratory burst (18) . The ability of sporozoite to traverse through and invade liver cells by membrane disruption allowing for movements in and out of cells (19, 20) ; has been attributed to thrombospondin-related anonymous protein (TRAP), a micronemal protein that mediates gliding, motility and invasion in the mammalian host (21, 22) . It is pertinent to note that simvastatin blocks the transformation of sporozoites to liver schizonts by concentrating in the hepatocytes. The major therapeutic effect attributable to simvastatin in the present study is due to relatively high concentration in the liver. Consequently, the need for further studies to explore and design derivatives of HMG-CoA reductase inhibitors with higher concentrations in plasma can never be over-emphasized.
In conclusion, the implication of present study indicates that the enhanced parasitological response to sulfadoxine-pyrimethamine may be attributed to modulating effects of simvastatin use. 
